The therapeutic potential of a venomous lizard: The use of glucagon-like peptide-1 analogues in the critically ill

Critical Care

Volumn 14, Issue 5, 2010, Pages

  Deane, Adam M ^a,b,c   Chapman, Marianne J ^a,b,c   Horowitz, Michael ^c,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; REPTILIAN PROTEIN; VENOM;

CRITICAL ILLNESS; DRUG HALF LIFE; HELODERMA SUSPECTUM; HUMAN; HYPOGLYCEMIA; LIZARD; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PRIORITY JOURNAL; ANIMAL; ISOLATION AND PURIFICATION;

ANIMALS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIZARDS; REPTILIAN PROTEINS; VENOMS;

EID: 80053300767     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9281     Document Type: Note

References (16)

1. Mecott GA, Herndon DN, Kulp GA, Brooks N, Al-Mousawi AM, Kraft R, Rivero HG, Williams FN, Branski LK, Jeschke MG. The use of exenatide in severely burned pediatric patients. Crit Care 2010, 14:R153. 10.1186/cc9222, 2945137, 20701787.
2. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986, 63:492-498. 10.1210/jcem-63-2-492, 3522621.
3. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307. 10.1172/JCI116186, 330027, 8423228.
4. Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996, 39:1546-1553. 10.1007/s001250050613, 8960841.
5. Deacon CF. What do we know about the secretion and degradation of incretin hormones?. Regul Pept 2005, 128(2):117-124. 10.1016/j.regpep.2004.06.007, 15780431.
6. Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 2004, 118(1-2):89-97. 10.1016/j.regpep.2003.11.003, 14759561.
7. Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004, 32:848-851. 10.1097/01.CCM.0000114811.60629.B5, 15090972.
8. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007, 100:824-829. 10.1016/j.amjcard.2007.05.022, 17719327.
9. Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009, 13:R67. 10.1186/cc7874, 2717426, 19439067.
10. Deane AM, Chapman MJ, Fraser RJ, Summers MJ, Zaknic AV, Storey JP, Jones KL, Rayner CK, Horowitz M. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med 2010, 38:1261-1269.
11. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143(8):559-69.
12. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082-3089. 10.1210/jc.2002-021545, 12843147.
13. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Peptides 2008, 151(1-3):123-129.
14. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705. 10.1016/S0140-6736(06)69705-5, 17098089.
15. Deane A, Chapman MJ, Fraser RJ, Horowitz M. Bench-to-bedside review: The gut as an endocrine organ in the critically ill. Crit Care 2010, 14:228. 10.1186/cc9039, 20887636.
16. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360:1283-1297. 10.1056/NEJMoa0810625, 19318384.